Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.

Harrold LR, Patel PA, Griffith J, Litman HJ, Feng H, Schlacher CA, Kremer JM.

Clin Rheumatol. 2019 Oct 21. doi: 10.1007/s10067-019-04727-7. [Epub ahead of print]

PMID:
31637609
2.

Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.

Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM.

Curr Med Res Opin. 2019 Oct 24:1-6. doi: 10.1080/03007995.2019.1680354. [Epub ahead of print]

PMID:
31612736
3.

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE.

J Dermatolog Treat. 2019 Oct 3:1-8. doi: 10.1080/09546634.2019.1656797. [Epub ahead of print]

PMID:
31581919
4.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.

PMID:
31501138
5.

Long-term, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-Based Registry.

Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD.

J Rheumatol. 2019 Aug 1. pii: jrheum.190260. doi: 10.3899/jrheum.190260. [Epub ahead of print]

6.

Patient- and Rheumatologist- Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.

Owensby JK, Chen L, O'Beirne R, Ruderman E, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI.

Arthritis Care Res (Hoboken). 2019 Apr 22. doi: 10.1002/acr.23907. [Epub ahead of print]

PMID:
31008566
7.

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.

Harrold LR, Litman HJ, Connolly SE, Alemao E, Kelly S, Rebello S, Hua W, Kremer JM.

Rheumatol Ther. 2019 Jun;6(2):217-230. doi: 10.1007/s40744-019-0149-3. Epub 2019 Mar 13.

8.

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.

J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034. Epub 2019 Jan 15.

PMID:
30647182
9.

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.

Harrold LR, Reed GW, Best J, Zlotnick S, Kremer JM.

Rheumatol Ther. 2018 Dec;5(2):507-523. doi: 10.1007/s40744-018-0127-1. Epub 2018 Oct 6.

10.

Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.

Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B.

Arthritis Care Res (Hoboken). 2019 Sep;71(9):1243-1248. doi: 10.1002/acr.23755. Epub 2019 Jul 19.

PMID:
30221841
11.

Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.

Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.

J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.

12.

Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):427-434. doi: 10.1002/acr.23607.

PMID:
29799677
13.

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M.

Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5.

14.

Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.

Larmore CJ, Boytsov NN, Gaich CL, Zhang X, Araujo AB, Rebello S, Salim BA, Reed GW, Harrold LR.

Rheumatol Ther. 2018 Jun;5(1):215-229. doi: 10.1007/s40744-017-0092-0. Epub 2018 Jan 10.

15.

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.

Solomon DH, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina E.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1551-1556. doi: 10.1002/acr.23508.

16.

Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1.

17.

Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

J Rheumatol. 2018 Jan;45(1):78-82. doi: 10.3899/jrheum.161567. Epub 2017 Oct 1.

PMID:
28966209
18.

Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL.

Semin Arthritis Rheum. 2018 Feb;47(4):472-477. doi: 10.1016/j.semarthrit.2017.07.010. Epub 2017 Aug 2.

PMID:
28947312
19.

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, Best J, Zlotnick S, Kremer JM, Greenberg JD.

Rheumatol Ther. 2017 Dec;4(2):405-417. doi: 10.1007/s40744-017-0081-3. Epub 2017 Sep 21.

20.

Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial.

Yu Z, Lu B, Agosti J, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Losina E, Katz JN, Solomon DH.

Arthritis Care Res (Hoboken). 2018 May;70(5):801-806. doi: 10.1002/acr.23343. Epub 2018 Apr 12.

21.

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM.

Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17.

22.

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

23.

Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial.

Solomon DH, Losina E, Lu B, Zak A, Corrigan C, Lee SB, Agosti J, Bitton A, Harrold LR, Pincus T, Radner H, Yu Z, Smolen JS, Fraenkel L, Katz JN.

Arthritis Rheumatol. 2017 Jul;69(7):1374-1380. doi: 10.1002/art.40111. Epub 2017 May 31.

24.

Sex differences in gout characteristics: tailoring care for women and men.

Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD.

BMC Musculoskelet Disord. 2017 Mar 14;18(1):108. doi: 10.1186/s12891-017-1465-9.

25.

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

Clin Rheumatol. 2017 Apr;36(4):895-901. doi: 10.1007/s10067-017-3593-x. Epub 2017 Mar 7.

PMID:
28271234
26.

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

Clin Rheumatol. 2017 Jun;36(6):1215-1220. doi: 10.1007/s10067-017-3588-7. Epub 2017 Mar 1.

27.

Digging into Debt: The Financial Burden Associated with the Otolaryngology Match.

Polacco MA, Lally J, Walls A, Harrold LR, Malekzadeh S, Chen EY.

Otolaryngol Head Neck Surg. 2017 Jun;156(6):1091-1096. doi: 10.1177/0194599816686538. Epub 2017 Jan 24.

PMID:
28116996
28.

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.

Arthritis Res Ther. 2016 Dec 1;18(1):280.

29.

Preoperative Pain and Function: Profiles of Patients Selected for Total Knee Arthroplasty.

Nguyen UD, Ayers DC, Li W, Harrold LR, Franklin PD.

J Arthroplasty. 2016 Nov;31(11):2402-2407.e2. doi: 10.1016/j.arth.2016.04.015. Epub 2016 Apr 27.

30.

Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients.

Boytsov N, Harrold LR, Mason MA, Gaich CL, Zhang X, Larmore CJ, Rebello S, Araujo AB.

Curr Med Res Opin. 2016 Dec;32(12):1959-1967. Epub 2016 Aug 25.

PMID:
27558077
31.

Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting.

Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ, Herrinton LJ.

Perm J. 2016 Fall;20(4):15-151. doi: 10.7812/TPP/15-151. Epub 2016 Jul 29.

32.

What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.

Tatlock S, Rüdell K, Panter C, Arbuckle R, Harrold LR, Taylor WJ, Symonds T.

Patient. 2017 Feb;10(1):65-79. doi: 10.1007/s40271-016-0184-x.

33.

A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.

Rathbun AM, Harrold LR, Reed GW.

Clin Ther. 2016 Jul;38(7):1759-1772.e3. doi: 10.1016/j.clinthera.2016.06.007. Epub 2016 Jun 29.

34.

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.

Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1888-1893. doi: 10.1002/acr.22912.

35.

Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry.

Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR.

J Rheumatol. 2016 May;43(5):924-30. doi: 10.3899/jrheum.150345. Epub 2016 Mar 15.

PMID:
26980578
36.

Objectively Measured Physical Activity and Symptoms Change in Knee Osteoarthritis.

Liu SH, Driban JB, Eaton CB, McAlindon TE, Harrold LR, Lapane KL.

Am J Med. 2016 May;129(5):497-505.e1. doi: 10.1016/j.amjmed.2015.12.029. Epub 2016 Feb 2.

37.

Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.

de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N.

Arthritis Care Res (Hoboken). 2016 May;68(5):667-72. doi: 10.1002/acr.22741.

38.
39.

Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.

Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD.

J Rheumatol. 2015 Jul;42(7):1090-8. doi: 10.3899/jrheum.141043. Epub 2015 May 1.

40.

Disease activity in rheumatoid arthritis and the risk of cardiovascular events.

Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg JD.

Arthritis Rheumatol. 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.

41.

Use of atypical antipsychotics in nursing homes and pharmaceutical marketing.

Pimentel CB, Donovan JL, Field TS, Gurwitz JH, Harrold LR, Kanaan AO, Lemay CA, Mazor KM, Tjia J, Briesacher BA.

J Am Geriatr Soc. 2015 Feb;63(2):297-301. doi: 10.1111/jgs.13180.

42.

Overcoming adherence issues and other barriers to optimal care in gout.

Nasser-Ghodsi N, Harrold LR.

Curr Opin Rheumatol. 2015 Mar;27(2):134-8. doi: 10.1097/BOR.0000000000000141. Review.

PMID:
25633242
43.

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.

Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD.

Arthritis Res Ther. 2016 Apr 26;18:94. doi: 10.1186/s13075-016-0992-3.

44.

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network.

Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM.

BMC Musculoskelet Disord. 2014 Nov 21;15:389. doi: 10.1186/1471-2474-15-389.

45.

Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity.

Rathbun AM, Harrold LR, Reed GW.

Arthritis Care Res (Hoboken). 2015 May;67(6):765-75. doi: 10.1002/acr.22515.

46.

Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms.

Rathbun AM, Harrold LR, Reed GW.

Clin Rheumatol. 2015 Apr;34(4):653-63. doi: 10.1007/s10067-014-2759-z. Epub 2014 Aug 27.

PMID:
25156674
47.

A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population.

Rathbun AM, Harrold LR, Reed GW.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):523-32. Epub 2014 Jul 1.

PMID:
24984165
48.

An electronic health record-based intervention to increase follow-up office visits and decrease rehospitalization in older adults.

Gurwitz JH, Field TS, Ogarek J, Tjia J, Cutrona SL, Harrold LR, Gagne SJ, Preusse P, Donovan JL, Kanaan AO, Reed G, Garber L.

J Am Geriatr Soc. 2014 May;62(5):865-71. doi: 10.1111/jgs.12798. Epub 2014 Apr 29.

49.

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.

Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD.

Ann Rheum Dis. 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936. Epub 2013 Dec 2.

50.

Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis.

Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR.

Am J Med. 2013 Dec;126(12):1089-98. doi: 10.1016/j.amjmed.2013.09.002.

Supplemental Content

Loading ...
Support Center